{"id":50845,"date":"2022-11-14T23:02:19","date_gmt":"2022-11-14T22:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lucid-diagnostics-provides-business-update-and-third-quarter-2022-financial-results\/"},"modified":"2022-11-14T23:02:19","modified_gmt":"2022-11-14T22:02:19","slug":"lucid-diagnostics-provides-business-update-and-third-quarter-2022-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lucid-diagnostics-provides-business-update-and-third-quarter-2022-financial-results\/","title":{"rendered":"Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results"},"content":{"rendered":"
\n

\nEsoGuard test volume increased 28% sequentially and 436% annually<\/b><\/i>\n<\/p>\n

\nConference call and webcast to be held today at 4:30 PM EDT<\/b><\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–#CheckYourFoodTube<\/a>—Lucid Diagnostics Inc.<\/a> (Nasdaq: LUCD) (\u201cLucid\u201d or the \u201cCompany\u201d), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc.<\/a> (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.\n<\/p>\n

<\/a><\/p>\n

\nConference Call and Webcast<\/b>\n<\/p>\n

\nA conference call and webcast for today\u2019s business update and third quarter 2022 financial results will take place at 4:30 PM EDT. <\/b>To access the conference call, listeners should dial 877-407-0789 toll-free in the U.S., and international listeners should dial 201-689-8562 and ask to join <\/b>the \u201cLucid Diagnostics Business Update Conference Call\u201d. The webcast<\/a> presentation and conference call will be available live and for replay at the investor relations section of the Company\u2019s website at https:\/\/ir.luciddx.com<\/a>. Following the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 toll-free in the U.S. or 412-317-6671, followed by the PIN number: 13732743.\n<\/p>\n

\nBusiness Update Highlights<\/b>\n<\/p>\n

\n\u201cWith recent transformational milestones behind us, the Lucid team is now intensely focused on executing on our long-term growth strategy and delivered solid results for the past quarter,\u201d said Lishan Aklog, M.D.<\/a>, Lucid\u2019s Chairman and Chief Executive Officer. \u201cI am particularly proud that the team is delivering these results well under budget for the quarter and year, as we continue to keep a close eye on cash preservation to protect our long-term position. Testing volume continues to grow at a steady clip, consistent with the \u2018mid-throttle\u2019 strategy we have implemented until reimbursement becomes more predictable. I am also gratified that the claims submission process, which we launched mid-quarter, is starting to bear fruit in terms of payments and recognized revenue.\u201d\n<\/p>\n

\nHighlights from the third quarter and recent weeks include:\n<\/p>\n